Ligand has assembled one of the largest portfolios of biopharmaceutical assets among our peers which provides investors the opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.
| Partner | Program | Technology | Indication | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical/IND | Phase 1 | Phase 2 | Phase 3/NDA | Approved | ||||
| Acrotech/CASI | Evomela | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Alvogen | Teriparatide | Pelican Expression Technology | Osteoporosis |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Alvogen | Voriconazole | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Amgen/Ono | Kyprolis | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Aziyo | ECM portfolio | ECM | Med Device/Cardiology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Baxter | Nexterone | Captisol | Cardiovascular Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Biocad | Teberif | Selexis SUREtechnology | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Exelixis/Daiichi-Sankyo | Minnebro | Other/NCE | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Gilead | Veklury | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Hikma Pharmaceuticals | Voriconazole (EU) | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Jazz Pharmaceuticals | RYLAZE™ | Pelican Expression Technology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Lundbeck | Carnexiv | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Melinta | Baxdela | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Merck | Noxafil IV | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Merck | VAXNEUVANCE™ | Pelican Expression Technology | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Nanjing King-Friend | Voriconazole (China and US) | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Par Pharmaceuticals | Posaconazole-Par | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | Duavee | Other/NCE | Women's Health |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | VFEND | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | Viviant/Conbriza | Other/NCE | Women's Health |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Sedor | Sesquient | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Serum Institute of India | CRM197-Pneumosil | Pelican Expression Technology | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus Cadila | Bryxta and Zybev | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus Cadila | Exemptia | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus Cadila | Vivitra | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus Cadila | Vortuxi | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Aldeyra | Reproxalap | Captisol | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Biocad | BCD-066 (Darbopoeitin) | Selexis SUREtechnology | Hematology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| IBC Generium | GNR-008 (Imiglugerase biosimilar) | Selexis SUREtechnology | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Marinus | Ganaxolone-IV | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Novan | SB206 | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Outlook Therapeutics | ONS-5010 | Selexis SUREtechnology | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Palvella Therapeutics | PTX-022 | Other/NCE | To Be Determined |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Serum Institute of India | CRM197 | Pelican Expression Technology | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Sunshine Lake Pharma | Vilazodone | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Travere Therapeutics | Sparsentan | Other/NCE | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Verona | Ensifentrine | Captisol | Respiratory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Xi'an Xintong | Pradefovir | HepDirect | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Cantex | CX-01 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Corvus | CPI-444 (Ciforadenant) | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
|
| Eisai | FYCOMPA (Perampanel) | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Elevation Oncology | Seribantumab | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| J-Pharma | JPH203-SBECD | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Merck | V116 | Pelican Expression Technology | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Opthea | OPT-302 | Selexis SUREtechnology | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Precision Biologics | NPC-1C (Ensituximab) | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Seelos | Aplindore | Other/NCE | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Sermonix | Lasofoxifene | Other/NCE | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| VentiRx | Motolimod (VTX-2337) | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-5211 | Other/NCE | Musculoskeletal Disorder |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-2809 | HepDirect | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Apotex | CE-Meloxicam | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Gedeon Richter | Bevacizumab biosimilar | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Jupiter Bioscience | Viright | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| MEI | ME-344 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Nucorion | NCO-48 Fumarate | LTP Technology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
|
| Phoenix Tissue Repair | PTR-01 | Selexis SUREtechnology | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Protagonist Therapeutics | PTG300 | Captisol | Hematology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Revision Therapeutics | Rev0100 | Captisol | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Sage | SAGE-689 | CNS |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
|
| Servier | S55746/S64315 | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
|
| Takeda | TAK-243 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Takeda | TAK-925 | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Vaxxas | Nanopatch | Captisol | To Be Determined |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| VentiRx | VTX-1463 | Captisol | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-0214 | Other/NCE | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Xi'an Xintong | MB07133 | HepDirect | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
Ligand’s partners currently have over 100 drug candidates in discovery/pre-clinical development or an IND has been filed
